Inactive Instrument

News Sienna Cancer Diagnostics Limited

Equities

SDX

AU000000SDX1

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

BARD1 Life Sciences Limited completed the acquisition of Sienna Cancer Diagnostics Limited from Merchant Funds Management Pty Ltd and other shareholders.	20-07-27	CI
Sienna Cancer Diagnostics Announces Change of Registered Office	20-06-26	CI
Sienna Cancer Diagnostics Limited Announces Distribution Agreement with Aenorasis S.A	20-06-18	CI
Sienna Cancer Diagnostics Appoints Triolab AB Exclusive Distributor in Sweden	20-06-01	CI
Sienna Cancer Diagnostics Limited Announces Distribution Agreement with Zotal Ltd	20-05-20	CI
Sienna Cancer Diagnostics Ltd. Appoints Scientle Innovations as its Exclusive Distributor in New Zealand	20-05-05	CI
Sienna Cancer Diagnostics Ltd H Enters into an Exclusive Worldwide Licence Agreement with the University of Adelaide to Develop and Commercialise Unique Cancer Probe, SubB2M	20-04-19	CI
BARD1 Life Sciences Limited entered into a merger implementation agreement to acquire Sienna Cancer Diagnostics Limited for AUD 24.7 million.	20-04-07	CI
Sienna Cancer Diagnostics Limited Appoints Geoff Mccaughan to Its Recently Formed Clinical Advisory Board	20-03-15	CI
Sienna Cancer Diagnostics : Closes Rights Issue Offer	20-02-24	PU
Sienna Cancer Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2019	20-02-20	CI
Sienna Cancer Diagnostics : makes Board Appointment	20-02-05	PU
Sienna Cancer Diagnostics : Increases European Presence Expanding into Finland with hTERT test	20-02-05	PU
Sienna Cancer Diagnostics Limited Appoints Immuno Diagnostic Oy as an Exclusive Distributor in Finland	20-02-05	CI
Sienna Cancer Diagnostics Limited Appoints Tony Di Pietro as a Director of its Board	20-02-05	CI
Sienna Cancer Diagnostics : Appendix 4C and Report on Quarterly Activities	20-01-31	PU
Sienna Cancer Diagnostics Limited Announces Clinical Advisory Board Appointments	20-01-29	CI
Sienna Cancer Diagnostics Ltd Announces the Initiation of South Korean Clinical Study Utilising the Company's Novel Adjunct Urine Cytology Test, the hTERT test	20-01-21	CI
Sienna Cancer Diagnostics : Substantial Take-up of Rights Issue Shortfall	20-01-21	PU
Sienna Cancer Diagnostics : Investor update January 2020	20-01-14	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sienna Cancer Diagnostics Limited

Equities

SDX

AU000000SDX1

Summary

Filters